TGA grants provisional approval to Hansa’s Idefirix as desensitisation treatment
The provisional approval comes with a duration of two years. It is based on the data from Phase II studies that enrolled highly sensitised patients who received imlifidase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.